RNA-electroporated T Cells for Cancer Immunotherapy

Overview

Journal Oncoimmunology

Specialty Allergy & Immunology

Date 2020 Oct 26

PMID 33101771

Citations 4

Authors

Fernanda Pohl-Guimaraes

Lan B Hoang-Minh

Duane A Mitchell

Affiliations

Soon will be listed here.

Abstract

Adoptive T cell therapy has proven effective against hematologic malignancies and demonstrated efficacy against a variety of solid tumors in preclinical studies and clinical trials. Nonetheless, antitumor responses against solid tumors remain modest, highlighting the need to enhance the effectiveness of this therapy. Genetic modification of T cells with RNA has been explored to enhance T-cell antigen specificity, effector function, and migration to tumor sites, thereby potentiating antitumor immunity. This review describes the rationale for RNA-electroporated T cell modifications and provides an overview of their applications in preclinical and clinical investigations for the treatment of hematologic malignancies and solid tumors.

Citing Articles

The Efficiency of Brain-Derived Neurotrophic Factor Secretion by mRNA-Electroporated Regulatory T Cells Is Highly Impacted by Their Activation Status.

Van den Bos J, Janssens I, Vermeulen M, Dams A, De Reu H, Peeters S Eur J Immunol. 2024; 55(2):e202451005.

PMID: 39703060 PMC: 11830389. DOI: 10.1002/eji.202451005.

BiTE-Secreting CAR-γδT as a Dual Targeting Strategy for the Treatment of Solid Tumors.

Huang S, Pan C, Lin Y, Chen M, Chen Y, Jan C Adv Sci (Weinh). 2023; 10(17):e2206856.

PMID: 37078788 PMC: 10265101. DOI: 10.1002/advs.202206856.

Intracavitary adoptive transfer of IL-12 mRNA-engineered tumor-specific CD8 T cells eradicates peritoneal metastases in mouse models.

Di Trani C, Cirella A, Arrizabalaga L, Bella A, Fernandez-Sendin M, Russo-Cabrera J Oncoimmunology. 2022; 12(1):2147317.

PMID: 36531687 PMC: 9757485. DOI: 10.1080/2162402X.2022.2147317.

Antibody-Based Immunotoxins for Colorectal Cancer Therapy.

Sanz L, Ibanez-Perez R, Guerrero-Ochoa P, Lacadena J, Anel A Biomedicines. 2021; 9(11).

PMID: 34829955 PMC: 8615520. DOI: 10.3390/biomedicines9111729.

Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T Cells.

Irving M, Lanitis E, Migliorini D, Ivics Z, Guedan S Hum Gene Ther. 2021; 32(19-20):1044-1058.

PMID: 34662233 PMC: 8697565. DOI: 10.1089/hum.2021.173.

References

Uslu U, Schuler G, Dorrie J, Schaft N . Combining a chimeric antigen receptor and a conventional T-cell receptor to generate T cells expressing two additional receptors (TETARs) for a multi-hit immunotherapy of melanoma. Exp Dermatol. 2016; 25(11):872-879. DOI: 10.1111/exd.13095. View

Kunii N, Zhao Y, Jiang S, Liu X, Scholler J, Balagopalan L . Enhanced function of redirected human T cells expressing linker for activation of T cells that is resistant to ubiquitylation. Hum Gene Ther. 2012; 24(1):27-37. PMC: 3555093. DOI: 10.1089/hum.2012.130. View

Riet T, Holzinger A, Dorrie J, Schaft N, Schuler G, Abken H . Nonviral RNA transfection to transiently modify T cells with chimeric antigen receptors for adoptive therapy. Methods Mol Biol. 2013; 969:187-201. DOI: 10.1007/978-1-62703-260-5_12. View

Dudley M, Wunderlich J, Robbins P, Yang J, Hwu P, Schwartzentruber D . Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002; 298(5594):850-4. PMC: 1764179. DOI: 10.1126/science.1076514. View

Dudley M, Wunderlich J, Yang J, Sherry R, Topalian S, Restifo N . Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005; 23(10):2346-57. PMC: 1475951. DOI: 10.1200/JCO.2005.00.240. View

Naguma E, Kawashima K, Nagase F, Nakashima I, Ohno R, Yamada K . Adoptive immunotherapy against a local or widespread tumor of a highly malignant and poorly immunogenic mouse leukemia L1210. Nihon Ketsueki Gakkai Zasshi. 1986; 49(6):1212-21. View

Darvin P, Toor S, Sasidharan Nair V, Elkord E . Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018; 50(12):1-11. PMC: 6292890. DOI: 10.1038/s12276-018-0191-1. View

Davila M, Riviere I, Wang X, Bartido S, Park J, Curran K . Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014; 6(224):224ra25. PMC: 4684949. DOI: 10.1126/scitranslmed.3008226. View

Porter D, Levine B, Kalos M, Bagg A, June C . Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365(8):725-33. PMC: 3387277. DOI: 10.1056/NEJMoa1103849. View

10.

Rosenberg S, Packard B, Aebersold P, Solomon D, Topalian S, TOY S . Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988; 319(25):1676-80. DOI: 10.1056/NEJM198812223192527. View

11.

Weiner L, Murray J, Shuptrine C . Antibody-based immunotherapy of cancer. Cell. 2012; 148(6):1081-4. PMC: 3310896. DOI: 10.1016/j.cell.2012.02.034. View

12.

Sandin L, Eriksson F, Ellmark P, Loskog A, Totterman T, Mangsbo S . Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo. Oncoimmunology. 2014; 3(1):e27614. PMC: 3962508. DOI: 10.4161/onci.27614. View

13.

Theobald M, Biggs J, Hernandez J, Lustgarten J, Labadie C, Sherman L . Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med. 1997; 185(5):833-41. PMC: 2196170. DOI: 10.1084/jem.185.5.833. View

14.

Cho D, Kim T, Lee W, Hwang Y, Cho H, Han H . Interleukin-18 and the costimulatory molecule B7-1 have a synergistic anti-tumor effect on murine melanoma; implication of combined immunotherapy for poorly immunogenic malignancy. J Invest Dermatol. 2000; 114(5):928-34. DOI: 10.1038/sj.jid.5600685. View

15.

Robbins P, Morgan R, Feldman S, Yang J, Sherry R, Dudley M . Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011; 29(7):917-24. PMC: 3068063. DOI: 10.1200/JCO.2010.32.2537. View

16.

Panjwani M, Smith J, Schutsky K, Gnanandarajah J, OConnor C, Powell Jr D . Feasibility and Safety of RNA-transfected CD20-specific Chimeric Antigen Receptor T Cells in Dogs with Spontaneous B Cell Lymphoma. Mol Ther. 2016; 24(9):1602-14. PMC: 5113111. DOI: 10.1038/mt.2016.146. View

17.

Yoon S, Lee J, Cho H, Kim E, Kim H, Park M . Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model. Cancer Gene Ther. 2008; 16(6):489-97. DOI: 10.1038/cgt.2008.98. View

18.

Sun S, Hao H, Yang G, Zhang Y, Fu Y . Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies. J Immunol Res. 2018; 2018:2386187. PMC: 5932485. DOI: 10.1155/2018/2386187. View

19.

Schutsky K, Song D, Lynn R, Smith J, Poussin M, Figini M . Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor. Oncotarget. 2015; 6(30):28911-28. PMC: 4745700. DOI: 10.18632/oncotarget.5029. View

20.

Dudley M, Rosenberg S . Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer. 2003; 3(9):666-75. PMC: 2305722. DOI: 10.1038/nrc1167. View